Critical Reviews in Oncology / Hematology
Volume 76, Issue 3 , Pages 153-172 , December 2010

How has proteomics informed transfusion biology so far?

  • Giancarlo Liumbruno

      Affiliations

    • Italian National Blood Centre, Istituto Superiore di Sanità, Rome, Italy
    • Immunohematology and Transfusion Medicine Unit, “San Giovanni Calibita” Fatebenefratelli Hospital, Rome, Italy
    • ,
  • Angelo D’Alessandro

      Affiliations

    • Italian National Blood Centre, Istituto Superiore di Sanità, Rome, Italy
    • Department of Environmental Sciences, Tuscia University, Viterbo, Italy
    • ,
  • Giuliano Grazzini

      Affiliations

    • Italian National Blood Centre, Istituto Superiore di Sanità, Rome, Italy
    • ,
  • Lello Zolla

      Affiliations

    • Department of Environmental Sciences, Tuscia University, Viterbo, Italy
    • Corresponding Author InformationCorresponding author at: Tuscia University, Largo dell’Università snc, 01100 Viterbo, Italy. Tel.: +39 0761 357 100; fax: +39 0761 357 630.

,Accepted 7 January 2010.

References 

  1. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860–921
  2. Subramanian G, Adams MD, Venter JC, Broder S. Implications of the human genome for understanding human biology and medicine. JAMA. 2001;286(18):2296–2307
  3. Stein LD. Human genome: end of the beginning. Nature. 2004;431(7011):915–916
  4. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature. 2004;429:464–468
  5. Shah RR. Pharmacogenetics in drug regulation: promise, potential and pitfalls. Philos Trans R Soc Lond B Biol Sci. 2005;360(1460):1617–1638
  6. Nebert DW, Zhang G, Vesell ES. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev. 2008;40(2):187–224
  7. Mann KG, Brummel-Ziedins K, Undas A, Butenas S. Does the genotype predict the phenotype? Evaluations of the hemostatic proteome. J Thromb Haemost. 2004;2(10):1727–1734
  8. Wasinger VC, Cordwell SJ, Cerpa-Poljak A, et al. Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium. Electrophoresis. 1995;16:1090–1094
  9. Marko-Varga G, Fehniger TE. Proteomics and disease: the challenges for technology and discovery. J Proteome Res. 2004;3:167–178
  10. Rappsilber J, Mann M. What does it mean to identify a protein in proteomics?. Trends Biochem Sci. 2002;27:74–78
  11. Zhu H, Bilgin M, Snyder M. Proteomics. Annu Rev Biochem. 2003;72:783–812
  12. Calvo KR, Liotta LA, Petricoin EF. Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy. Biosci Rep. 2005;25(1–2):107–125
  13. Unwin RD, Whetton AD. How will haematologists use proteomics?. Blood Rev. 2007;21(6):315–326
  14. Thadikkaran L, Siegenthaler MA, Crettaz D, et al. Recent advances in blood-related proteomics. Proteomics. 2005;5:3019–3034
  15. Braziel RM, Shipp MA, Feldman AL, et al. Molecular diagnostics. Hematol Am Soc Hematol Educ Program. 2003;1:279–293
  16. Wiltgen M, Tilz GP. DNA microarray analysis: principles and clinical impact. Hematology. 2007;12(4):271–287
  17. Anderson L, Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis. 1997;18(3–4):533–537
  18. Anderson NL, Anderson NG. Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis. 1998;19(11):1853–1861
  19. Cristea IM, Gaskell SJ, Whetton AD. Proteomics techniques and their application to hematology. Blood. 2004;103:3624–3634
  20. de Hoog CL, Mann M. Proteomics. Annu Rev Genomics Hum Genet. 2004;5:267–293
  21. Liumbruno G, D’Alessandro A, Grazzini G, Zolla L. Blood-related proteomics. J Proteomics. 2009;
  22. Rees-Unwin KS, Morgan GJ, Davies FE. Proteomics and the haematologist. Clin Lab Haem. 2004;26:77–86
  23. Greinacher A, Warkentin TE. Transfusion medicine in the era of genomics and proteomics. Transfus Med Rev. 2005;19:288–294
  24. Queloz PA, Thadikkaran L, Crettaz D, Rossier JS, Barelli S, Tissot JD. Proteomics and transfusion medicine: future perspectives. Proteomics. 2006;6:5605–5614
  25. Page MJ, Griffiths TAM, Bleackley MR, MacGillivray RTA. Proteomics: applications relevant to transfusion medicine. Transfus Med Rev. 2006;20:63–74
  26. Thiele T, Steil L, Völker U, Greinacher A. Proteomics of blood-based therapeutics. BioDrugs. 2007;21:179–193
  27. Liumbruno GM. Proteomics: applications in transfusion medicine. Blood Transfus. 2008;6(2):70–85
  28. Liumbruno G, D’Amici GM, Grazzini G, Zolla L. Transfusion medicine in the era of proteomics. J Proteomics. 2008;71(1):34–45
  29. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002;1:845–867
  30. Righetti PG, Castagna A, Herbert B, Candiano G. How to bring the “unseen” proteome to the limelight via electrophoretic pre-fractionation techniques. Biosci Rep. 2005;25(1–2):3–17
  31. Pieper R, Gatlin CL, Makusky AJ, et al. The human serum proteome: display of nearly 3700 chromatographically separated protein spots on two dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics. 2003;3:1345–1364
  32. Echan LA, Tang HY, Ali-Khan N, Lee KB, Speicher DW. Depletion of multiple high-abundance proteins improves the protein profiling capacities of human serum and plasma. Proteomics. 2005;5:3292–3303
  33. Heller M, Michel PE, Morier P, et al. Two-stage off-gel isoelectric focusing: protein followed by peptide fractionation and application to proteome analysis of human plasma. Electrophoresis. 2005;26(6):1174–1188
  34. Boschetti E, Righetti PG. The art of observing rare protein species in proteomes with peptide ligand libraries. Proteomics. 2009;
  35. Zhou M, Lucas DA, Chan KC, et al. An investigation into the human serum interactome. Electrophoresis. 2004;25:1289–1298
  36. Granger J, Siddiqui J, Copeland S, Remick D. Albumin depletion of human plasma also removes low abundance proteins including the cytokines. Proteomics. 2005;5(18):4713–4718
  37. Yocum AK, Yu K, Oe T, Blair IA. Effect of immunoaffinity depletion of human serum during proteomic investigations. J Proteome Res. 2005;4(5):1722–1731
  38. Petricoin EF, Belluco C, Araujo RP, Liotta LA. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer. 2006;6(12):961–967
  39. Atallah E, Schiffer CA. Granulocyte transfusion. Curr Opin Hematol. 2006;13(1):45–49
  40. Peters C. Granulocyte transfusions in neutropenic patients: beneficial effects proven?. Vox Sang. 2009;96(4):275–283
  41. Allain JP, Bianco C, Blajchman MA, Brecher ME, Busch M, Leiby D, et al. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev. 2005;19(2):110–126
  42. De Rosa MC, Carelli Alinovi C, Galtieri A, Scatena R, Giardina B. The plasma membrane of erythrocytes plays a fundamental role in the transport of oxygen, carbon dioxide and nitric oxide and in the maintenance of the reduced state of the heme iron. Gene. 2007;398:162–171
  43. Kooyman DL, Byrne GW, McClellan S, et al. In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science. 1995;269(5220):89–92
  44. Civenni G, Test ST, Brodbeck U, Butikofer P. In vitro incorporation of GPI-anchored proteins into human erythrocytes and their fate in the membrane. Blood. 1998;91:1784–1792
  45. Schifferli JA, Taylor RP. Physiological and pathological aspects of circulating immune complexes. Kidney Int. 1989;35:993–1003
  46. Palis J. Ontogeny of erythropoiesis. Curr Opin Hematol. 2008;15(3):155–161
  47. Koury MJ, Sawyer ST, Brandt SJ. New insights into erythropoiesis. Curr Opin Hematol. 2002;9(2):93–100
  48. Grazzini G. The Italian blood system. Blood Transfus. 2009;7(1):4–5
  49. Rosenblum BB. Two-dimensional gel electrophoresis of erythrocyte membrane proteins. Prog Clin Biol Res. 1981;56:251–268
  50. Low TY, Seow TK, Chung MC. Separation of human erythrocyte membrane associated proteins with one-dimensional and two-dimensional gel electrophoresis followed by identification with matrix-assisted laser desorption/ionization-time of flight mass spectrometry. Proteomics. 2002;2:1229–1239
  51. Goodman SR, Kurdia A, Ammann L, Kakhniashvili D, Daescu O. The human red blood cell proteome and interactome. Exp Biol Med (Maywood). 2007;232:1391–1408
  52. Roux-Dalvai F, Gonzalez de Peredo A, Simó C, et al. Extensive analysis of the cytoplasmic proteome of human erythrocytes using the peptide ligand library technology and advanced mass spectrometry. Mol Cell Proteomics. 2008;7(11):2254–2269
  53. Florens L, Liu X, Wang Y, et al. Proteomics approach reveals novel proteins on 5the surface of malaria-infected erythrocytes. Mol Biochem Parasitol. 2004;135:1–11
  54. Körbel S, Büchse T, Prietzsch H, et al. Phosphoprotein profiling of erythropoietin receptor-dependent pathways using different proteomic strategies. Proteomics. 2005;5(1):91–100
  55. Jiang M, Jia L, Jiang W, et al. Protein disregulation in red blood cell membranes of type 2 diabetic patients. Biochem Biophys Res Commun. 2003;309:196–200
  56. Kakhniashvili DG, Griko NB, Bulla LA, Goodman SR. The proteomics of sickle cell disease: profiling of erythrocyte membrane proteins by 2D-DIGE and tandem mass spectrometry. Exp Biol Med. 2005;230:787–792
  57. Chou J, Choudhary PK, Goodman SR. Protein profiling of sickle cell versus control RBC core membrane skeletons by ICAT technology and tandem mass spectrometry. Cell Mol Biol Lett. 2006;11(3):326–337
  58. Ghatpande SS, Choudhary PK, Quinn CT, Goodman SR. Pharmaco-proteomic study of hydroxyurea-induced modifications in the sickle red blood cell membrane proteome. Exp Biol Med. 2008;233(12):1510–1517
  59. Haynes J, Obiako B, Hester RB, Baliga BS, Stevens T. Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium. Am J Physiol Heart Circ Physiol. 2008;294:H379–H385
  60. Prabakaran S, Wengenroth M, Lockstone HE, Lilley K, Leweke FM, Bahn S. 2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia. J Proteome Res. 2007;6(1):141–149
  61. Högman CF, Meryman HT. Red blood cells intended for transfusion: quality criteria revisited. Transfusion. 2006;46(1):137–142
  62. Novotny VM. Red cell transfusion in medicine: future challenges. Transfus Clin Biol. 2007;14(6):538–541
  63. Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. Lancet. 2007;370(9585):415–426
  64. Hess JR. An update on solutions for red cell storage. Vox Sang. 2006;91(1):13–19
  65. Hess JR. Red cell freezing and its impact on the supply chain. Transfus Med. 2004;14(1):1–8
  66. Council of Europe . Guide to the preparation, use and quality assurance of blood components. Recommendation no R (95) 15 on the preparation, use and quality assurance of blood components. 14th ed.. Strasbourg: Council of Europe Press; 2008;
  67. Valeri CR, Ragno G, Pivacek LE, et al. An experiment with glycerol-frozen red blood cells stored at −80 degrees C for up to 37 years. Vox Sang. 2000;79(3):168–174
  68. Yoshida T, AuBuchon JP, Tryzelaar L, Foster KY, Bitensky MW. Extended storage of red blood cells under anaerobic conditions. Vox Sang. 2007;92(1):22–31
  69. Yoshida T, AuBuchon JP, Dumont LJ, et al. The effects of additive solution pH and metabolic rejuvenation on anaerobic storage of red cells. Transfusion. 2008;48(10):2096–2105
  70. Dumont LJ, Yoshida T, AuBuchon JP. Anaerobic storage of red blood cells in a novel additive solution improves in vivo recovery. Transfusion. 2009;49(3):458–464
  71. D’Amici GM, Rinalducci S, Zolla L. Proteomic analysis of RBC membrane protein degradation during blood storage. J Proteome Res. 2007;6:3242–3255
  72. Messana I, Ferroni L, Misiti F, et al. Blood bank conditions and RBCs: the progressive loss of metabolic modulation. Transfusion. 2000;40(3):353–360
  73. Annis AM, Glenister KM, Killian JJ, Sparrow RL. Proteomic analysis of supernatants of stored red blood cell products. Transfusion. 2005;45:1426–1433
  74. Bosman GJ, Lasonder E, Luten M, Roerdinkholder-Stoelwinder B, Novotný VM, Bos H, et al. The proteome of red cell membranes and vesicles during storage in blood bank conditions. Transfusion. 2008;48(5):827–835
  75. Schenk BI, Petersen F, Flad HD, Brandt E. Platelet-derived chemokines CXC chemokine ligand (CXC)7, connective tissue-activating peptide III, and CXCL4 differentially affect and cross-regulate neutrophil adhesion and transendothelial migration. J Immunol. 2002;169:2602–2610
  76. Sparrow RL, Patton KA. Supernatant from stored red blood cell primes inflammatory cells: influence of prestorage white cell reduction. Transfusion. 2004;44:722–773
  77. Annis AM, Sparrow RL. Storage duration and white blood cell content of red blood cell (RBC) products increases adhesion of stored RBCs to endothelium under flow conditions. Transfusion. 2006;46:1561–1567
  78. Greenwalt TJ. The how and why of exocytic vesicles. Transfusion. 2006;46:143–152
  79. Bosman GJ, Werre JM, Willekens FL, Novotný VM. Erythrocyte ageing in vivo and in vitro: structural aspects and implications for transfusion. Transfus Med. 2008;18(6):335–347
  80. D’Alessandro A, Righetti PG, Zolla L. The red blood cell proteome and interactome: an update. J Proteome Res. 2009;
  81. Patel SR, Hartwig JH, Italiano JE. The biogenesis of platelets from megakaryocyte proplatelets. J Clin Invest. 2005;115:3348–3354
  82. Li J, Xia Y, Bertino AM, Coburn JP, Kuter DJ. The mechanism of apoptosis in human platelets during storage. Transfusion. 2000;40(11):1320–1329
  83. White JG. Electron microscopic studies of platelet secretion. Prog Hemostasis Thromb. 1974;2:49–98
  84. White JG. Interaction of membrane systems in blood platelets. Am J Pathol. 1972;66:295–312
  85. Cutler L, Rodan G, Feinstein MB. Cytochemical localization of adenylate cyclase and of calcium ion, magnesium ion-activated ATPases in the dense tubular system of human blood platelets. Biochim Biophys Acta. 1978;542:357–371
  86. McRedmond JP, Park SD, Reilly DF. Integration of proteomics and genomics in platelets: a profile of platelet proteins and platelet-specific genes. Mol Cell Proteomics. 2004;3:133–144
  87. Gnatenko DV, Dunn JJ, McCorkle SR. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood. 2003;101:2285–2293
  88. Weyrich AS, Lindemann S, Tolley ND. Change in protein phenotype without a nucleus: translational control in platelets. Semin Thromb Hemost. 2004;30:491–498
  89. Gailani D, Renne T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol. 2007;27:2507–2513
  90. Kolev K, Machovich R. Molecular and cellular modulation of fibrinolysis. Thromb Haemost. 2003;89:610–621
  91. Clemetson KJ, Capitanio A, Lüscher EF. High resolution two-dimensional gel electrophoresis of the proteins and glycoproteins of human blood platelets and platelet membranes. Biochim Biophys Acta. 1979;553:11–24
  92. Gravel P, Sanchez JC, Walzer C, et al. Human blood platelet protein map established by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis. 1995;16:1152–1159
  93. Moebius J, Zahedi RP, Lewandrowski U, Berger C, Walter U, Sickmann A. The human platelet membrane proteome reveals several new potential membrane proteins. Mol Cell Proteomics. 2005;4(11):1754–1761
  94. Guerrier L, Claverol S, Fortis F, et al. Exploring the platelet proteome via combinatorial, hexapeptide ligand libraries. J Proteome Res. 2007;6(11):4290–4303
  95. O’Neill EE, Brock CJ, von Kriegsheim AF, et al. Towards complete analysis of the platelet proteome. Proteomics. 2002;2:288–305
  96. García A, Prabhakar S, Brock CJ, et al. Extensive analysis of the human platelet proteome by two-dimensional gel electrophoresis and mass spectrometry. Proteomics. 2004;4:656–668
  97. Claeys D, Geering K, Meyer BJ. Two-dimensional Blue Native/sodium dodecyl sulfate gel electrophoresis for analysis of multimeric proteins in platelets. Electrophoresis. 2005;26:1189–1199
  98. Immler D, Gremm D, Kirsch D, Spengler B, Presek P, Meyer HE. Identification of phosphorylated proteins from thrombin-activated human platelets isolated by two-dimensional gel electrophoresis by electrospray ionization-tandem mass spectrometry (ESI-MS/MS) and liquid chromatography–electrospray ionization-mass spectrometry (LC–ESI-MS). Electrophoresis. 1998;19(6):1015–1023
  99. Marcus K, Immler D, Sternberger J, Meyer HE. Identification of platelet proteins separated by two-dimensional gel electrophoresis and analyzed by matrix assisted laser desorption/ionization-time of flight-mass spectrometry and detection of tyrosine-phosphorylated proteins. Electrophoresis. 2000;21(13):2622–2636
  100. Marcus K, Moebius J, Meyer HE. Differential analysis of phosphorylated proteins in resting and thrombin-stimulated human platelets. Anal Bioanal Chem. 2003;376(7):973–993
  101. Maguire PB, Wynne KJ, Harney DF, O’Donoghue NM, Stephens G, Fitzgerald DJ. Identification of the phosphotyrosine proteome from thrombin activated platelets. Proteomics. 2002;2(6):642–648
  102. García A, Prabhakar S, Hughan S, et al. Differential proteome analysis of TRAP-activated platelets: involvement of DOK-2 and phosphorylation of RGS proteins. Blood. 2004;103(6):2088–2095
  103. García A, Senis YA, Antrobus R, et al. A global proteomics approach identifies novel phosphorylated signaling proteins in GPVI-activated platelets: involvement of G6f, a novel platelet Grb2-binding membrane adapter. Proteomics. 2006;6(19):5332–5343
  104. Lewandrowski U, Moebius J, Walter U, Sickmann A. Elucidation of N-glycosylation sites on human platelet proteins: a glycoproteomic approach. Mol Cell Proteomics. 2006;5(2):226–233
  105. Coppinger JA, Cagney G, Toomey S, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood. 2004;103(6):2096–2104
  106. Slichter SJ. Controversies in platelet transfusion therapy. Annu Rev Med. 1980;31:509–540
  107. Higby DJ, Cohen E, Holland JF, Sinks S. The prophylactic treatment of thrombocytopenic leukemic patients with platelets: a double blind study. Transfusion. 1974;14:440–446
  108. Holme S, Vaidja K, Murphy S. Platelet storage at 22°C: effect of type of agitation on morphology, viability, and function in vitro. Blood. 1978;52:425–435
  109. Blajchman MA. Incidence and significance of the bacterial contamination of blood components. Dev Biol. 2002;108:59–67
  110. Hillyer CD, Josephson CD, Blajchman MA, Vostal JG, Epstein JS, Goodman JL. Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine. Hematol Am Soc Hematol Educ Program. 2003;1:575–589
  111. Ben-Hur E, Moor ACE, Margolis-Nunno H, et al. The photodecontamination of cellular blood components: mechanisms and use of photosensitization in transfusion medicine. Transfus Med Rev. 1996;10:15–22
  112. Corash L. Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates: current research perspectives. Transfus Med Rev. 1999;13:18–30
  113. Chapman J. Progress in improving the pathogen safety of red cell concentrates. Vox Sang. 2000;78(2):203–204
  114. Goodrich RP. The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang. 2000;78(2):211–215
  115. Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion. 1997;37:423–435
  116. Klinger MH. The storage lesions of platelets: ultrastructural and functional aspects. Ann Hematol. 1996;73:103–112
  117. Seghatchian J, Krailadsiri P. The platelet storage lesion. Transfus Med Rev. 1997;11:130–144
  118. Cardigan R, Turner C, Harrison P. Current methods of assessing platelet function: relevance to transfusion medicine. Vox Sang. 2005;88:153–163
  119. Snyder EL, Dunn BE, Giometti CS, et al. Protein changes occurring during storage of platelet concentrates. A two-dimensional gel electrophoresis analysis. Transfusion. 1987;27:335–341
  120. Thiele T, Steil L, Gebhard S, et al. Profiling of alterations in platelet proteins during storage of platelet concentrates. Transfusion. 2007;47:1221–1233
  121. Glenister KM, Payne KA, Sparrow RL. Proteomic analysis of supernatant from pooled buffy-coat platelet concentrates throughout 7-day storage. Transfusion. 2008;48:99–107
  122. Wurtz V, Hechler B, Ohlmann P, et al. Identification of platelet factor 4 and β-thromboglobulin by profiling and liquid chromatography tandem mass spectrometry of supernatant peptides in stored apheresis and buffy-coat platelet concentrates. Transfusion. 2007;47:1099–1100[letter]
  123. Maynard DM, Heijnen HF, Horne MK, White JG, Gahl WA. Proteomic analysis of platelet alpha-granules using mass spectrometry. J Thromb Haemost. 2007;5(September (9)):1945–1955
  124. Albanyan AM, Murphy MF, Rasmussen JT, Heegaard CW, Harrison P. Measurement of phosphatidylserine exposure during storage of platelet concentrates using the novel probe lactadherin: a comparison study with annexin V. Transfusion. 2009;49(1):99–107
  125. Ryu SW, Suh IB, Cho Y. Protein profile changes in platelet concentrates according to storage and leukoreduction-analysis using proteomics technology. Korean J Lab Med. 2008;28(1):53–63
  126. Thon JN, Schubert P, Duguay M, et al. Comprehensive proteomic analysis of protein changes during platelet storage requires complementary proteomic approaches. Transfusion. 2008;48(3):425–435
  127. Springer D, Miller J, Spinelli S, et al. Platelet proteome changes associated with diabetes and during platelet storage for transfusion. J Proteome Res. 2009;doi:10.1021/pr800885j
  128. Sacristan D, Marques M, Zamorano-Leon JJ, et al. Modifications by Olmesartan medoxomil treatment of the platelet protein profile of moderate hypertensive patients. Proteomics Clin Appl. 2008;2:1300–1312
  129. Garritsen HS, Fan AX, Bosse N, et al. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for genotyping of human platelet-specific antigens. Transfusion. 2009;49(2):252–258
  130. Kroll H, Yates J, Santoso S. Immunization against a lowfrequency human platelet alloantigen in fetal alloimmune thrombocytopenia is not a single event: characterization by the combined use of reference DNA and novel allele specific cell lines expressing recombinant antigens. Transfusion. 2005;45:353–358
  131. Kaplan C. Neonatal alloimmune thrombocytopenia: a 50-year story. Immunohematology. 2007;23:9–13
  132. Rosenberg N, Dardik R. Post-transfusion purpura—when and why?. Isr Med Assoc J. 2006;8:709–710
  133. Cooling L. ABO and platelet transfusion therapy. Immunohematology. 2007;23:20–33
  134. Wu YY, Csako G. Rapid and/or high-throughput genotyping for human red blood cell, platelet and leukocyte antigens, and forensic applications. Clin Chim Acta. 2006;363(1–2):165–176
  135. Fountoulakis M, Juranville JF, Jiang L, et al. Depletion of the high-abundance plasma proteins. Amino Acids. 2004;27(3–4):249–259
  136. Tiselius A. Electrophoresis of serum globulin, I. Biochem J. 1937;31(2):313–317
  137. Anderson L, Anderson NG. High resolution two-dimensional electrophoresis of human plasma proteins. Proc Natl Acad Sci USA. 1977;74:5421–5425
  138. O’Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem. 1975;250(10):4007–4021
  139. Tracy RP, Currie RM, Young DS. Two-dimensional gel electrophoresis of serum specimens from a normal population. Clin Chem. 1982;28(4;2):890–899
  140. Harrison H, Miller K, Ober C, Refetoff S, Dick M, Elias S. Identification of a serum protein polymorphism via two-dimensional electrophoresis. Family and population studies in two genetically isolated groups: North American Hutterites and Australian aborigines. Am J Hum Genet. 1991;48(2):362–369
  141. Gravel P, Golaz O, Walzer C, Hochstrasser DF, Turler H, Balant LP. Analysis of glycoproteins separated by two-dimensional gel electrophoresis using lectin blotting revealed by chemiluminescence. Anal Biochem. 1994;221(1):66–71
  142. Henry H, Froehlich F, Perret R, et al. Microheterogeneity of serum glycoproteins in patients with chronic alcohol abuse compared with carbohydrate-deficient glycoprotein syndrome type I. Clin Chem. 1999;45(9):1408–1413
  143. Richter R, Schulz-Knappe P, Schrader M, et al. Composition of the peptide fraction in human blood plasma: database of circulating human peptides. J Chromatogr B Biomed Sci Appl. 1999;726(1–2):25–35
  144. Omenn GS, States DJ, Adamski M, et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics. 2005;5(13):3226–3245
  145. Li X, Gong Y, Wang Y, et al. Comparison of alternative analytical techniques for the characterisation of the human serum proteome in HUPO Plasma Proteome Project. Proteomics. 2005;5(13):3423–3441
  146. Smalley DM, Root KE, Cho H, Ross MM, Ley K. Proteomic discovery of 21 proteins expressed in human plasma-derived but not platelet-derived microparticles. Thromb Haemost. 2007;97(1):67–80
  147. Solheim BG, Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apher Sci. 2006;35:83–90
  148. Tissot JD, Hochstrasser DF, Schneider B, Morgenthaler JJ, Schneider P. No evidence for protein modifications in fresh frozen plasma after photochemical treatment: an analysis by high-resolution two-dimensional electrophoresis. Br J Haematol. 1994;86:143–146
  149. Wagner SJ, CifoneMA , Murli H, Dodd RY, Myhr B. Mammalian genotoxicity assessment of methylene blue in plasma: implications for virus inactivation. Transfusion. 1995;35:407–413
  150. AuBuchon JP, Pickard C, Herschel L, O’Connor JL, Lee E. Removal of methylene blue from plasma via an adsorbent filter. Vox Sang. 1998;74:1–6
  151. Riggert J, Humpe A, Legler TJ, Wolf C, Simson G, Köhler M. Filtration of methylene blue-photo oxidized plasma: influence on coagulation and cellular contamination. Transfusion. 2001;41:82–86
  152. Crettaz D, Sensebe L, Vu DH, et al. Proteomics of methylene blue photo-treated plasma before and after removal of the dye by an absorbent filter. Proteomics. 2004;4:881–891
  153. Steil L, Thiele T, Hammer E, et al. Proteomic characterization of freeze-dried human plasma: providing treatment of bleeding disorders without the need for a cold chain. Transfusion. 2008;48(11):2356–2363
  154. Qian WJ, Kaleta DT, Petritis BO, et al. Enhanced detection of low abundance human plasma proteins using a tandem IgY12-SuperMix immunoaffinity separation strategy. Mol Cell Proteomics. 2008;7(10):1963–1973
  155. Schenk S, Schoenhals GJ, de Souza G, Mann M. A high confidence, manually validated human blood plasma protein reference set. BMC Med Genomics. 2008;1:41
  156. Zheng X, Wu SL, Hincapie M, Hancock WS. Study of the human plasma proteome of rheumatoid arthritis. J Chromatogr A. 2009;
  157. Muthusamy B, Hanumanthu G, Suresh S, Rekha B, Srinivas D, Karthick L, et al. Plasma Proteome Database as a resource for proteomics research. Proteomics 2005;5(13):3531–6. Available at: www.plasmaproteomedatabase.org [last accessed on the 15th June 2009].
  158. Omenn GS, Aebersold R, Paik YK. 7(th) HUPO World Congress of Proteomics: launching the second phase of the HUPO Plasma Proteome Project (PPP-2) 16–20 August 2008, Amsterdam, The Netherlands. Proteomics. 2009;9(1):4–6
  159. Janzi M, Odling J, Pan-Hammarström Q, et al. Serum microarrays for large scale screening of protein levels. Mol Cell Proteomics. 2005;4(12):1942–1947
  160. Gast MC, Van Gils CH, Wessels LF, et al. Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS. Oncol Rep. 2009;22(1):205–213
  161. Schaub NP, Jones KJ, Nyalwidhe JO, et al. Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients. J Am Coll Surg. 2009;208(5):970–978
  162. Fiedler GM, Leichtle AB, Kase J, et al. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating peptide associated with pancreatic cancer. Clin Cancer Res. 2009;15(11):3812–3819
  163. Lee NP, Chen L, Lin MC, et al. Proteomic expression signature distinguishes cancerous and nonmalignant tissues in hepatocellular carcinoma. J Proteome Res. 2009;8(3):1293–1303
  164. Oh JH, Lotan Y, Gurnani P, Rosenblatt KP, Gao J. Prostate cancer biomarker discovery using high performance mass spectral serum profiling. Comput Methods Programs Biomed. 2009;
  165. Schwamborn K, Krieg RC, Grosse J, et al. Serum proteomic profiling in patients with bladder cancer. Eur Urol. 2009;
  166. Hübel K, Dale DC, Liles WC. Granulocyte transfusion therapy: update on potential clinical applications. Curr Opin Hematol. 2001;8:161–164
  167. Price TH. Granulocyte transfusion: current status. Semin Hematol. 2007;44:15–23
  168. Hübel K, Rodger E, Gaviria JM, et al. Effective storage of granulocytes collected by centrifugation leukapheresis from donors stimulated with granulocyte-colony-stimulating factor. Transfusion. 2005;45:1876–1889
  169. Italian Ministry of Health. Decree of March 3rd, 2005. Characteristics and modalities for blood and blood components donation. Gazzetta Ufficiale della Repubblica Italiana n. 85, April 13th, 2005.
  170. Morris CF, Castro MS, Fontes W. Neutrophil proteome: lessons from different standpoints. Protein Pept Lett. 2008;15(9):995–1001
  171. Boussac M, Garin J. Calcium-dependent secretion in human neutrophils: a proteomic approach. Electrophoresis. 2000;21:665–672
  172. Avram D, Romijn EP, Pap EH, Heck AJ, Wirtz KW. Identification of proteins in activated human neutrophils susceptible to tyrosyl radical attack. A proteomic study using a tyrosylating fluorophore. Proteomics. 2004;4(8):2397–2407
  173. Lominadze G, Powell DW, Luerman GC, Link AJ, Ward RA, McLeish KR. Proteomic analysis of human neutrophil granules. Mol Cell Proteomics. 2005;4(10):1503–1521
  174. Feuk-Lagerstedt E, Movitz C, Pellmé S, Dahlgren C, Karlsson A. Lipid raft proteome of the human neutrophil azurophil granule. Proteomics. 2007;7(2):194–205
  175. Füllekrug J, Simons K. Lipid rafts and apical membrane traffic. Ann NY Acad Sci. 2004;1014:164–169
  176. Razzaq TM, Ozegbe P, Jury EC, Sembi P, Blackwell NM, Kabouridis PS. Regulation of T-cell receptor signalling by membrane microdomains. Immunology. 2004;113(4):413–426
  177. Ministero del Lavoro, della Salute e delle Politiche Sociali. Uso appropriato delle cellule staminali del sangue del cordone ombelicale. Elementi informativi essenziali; 2009. Available at: http://www.ministerosalute.it/imgs/C_17_primopianoNuovo_228_documenti_itemDocumenti_0_fileDocumento.pdf [last accessed on the 26th of March 2009].
  178. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351:2265–2275
  179. Takahashi S, Iseki T, Ooi J, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood. 2004;104:3813–3820
  180. Brand A, Rebulla P, Engelfriet CP, et al. Cord blood banking. Vox Sang. 2008;95(4):335–348
  181. Koike K. Cryopreservation of pluripotent and committed hemopoietic progenitor cells from human bone marrow and cord blood. Acta Paediatr Jpn. 1983;25:275
  182. Zenzmaier C, Kollroser M, Gesslbauer B, Jandrositz A, Preisegger KH, Kungl AJ. Preliminary 2-D chromatographic investigation of the human stem cell proteome. Biochem Biophys Res Commun. 2003;310(2):483–490
  183. Zenzmaier C, Gesslbauer B, Grobuschek N, Jandrositz A, Preisegger KH, Kungl AJ. Proteomic profiling of human stem cells derived from umbilical cord blood. Biochem Biophys Res Commun. 2005;328(4):968–972
  184. Wei YQ, Feng R, Yi ZS, Liu QF. Establishment of two-dimensional gel electrophoresis profiles of proteome from CD34(+) hematopoietic stem/progenitor cells. Di Yi Jun Yi Da Xue Xue Bao. 2003;23(11):1161–1164
  185. Tao W, Wang M, Voss ED, et al. Comparative proteomic analysis of human CD34+ stem/progenitor cells and mature CD15+ myeloid cells. Stem Cells. 2004;22(6):1003–1014
  186. Liu F, Lu J, Fan HH, et al. Insights into human CD34+ hematopoietic stem/progenitor cells through a systematically proteomic survey coupled with transcriptome. Proteomics. 2006;6(9):2673–2692
  187. Unwin RD, Smith DL, Blinco D, et al. Quantitative proteomics reveals posttranslational control as a regulatory factor in primary hematopoietic stem cells. Blood. 2006;107(12):4687–4694
  188. D’Alessandro A, Liumbruno G, Grazzini G, Pupella S, Lombardini L, Zolla L. Umbilical cord blood stem cells: towards a proteomic approach. J Proteomics. 2009;
  189. Theilgaard-Mönch K, Raaschou-Jensen K, Schjødt K, et al. Pluripotent and myeloid-committed CD34+ subsets in hematopoietic stem cell allografts. Bone Marrow Transplant. 2003;32(12):1125–1133
  190. Kaiser T, Kamal H, Rank A, et al. Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104:340–349
  191. Weissinger EM, Schiffer E, Hertenstein B, et al. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2007;109(12):5511–5519
  192. Wang H, Clouthier SG, Galchev V, et al. Intactprotein-based high-resolution three-dimensional quantitative analysis system for proteome profiling of biological fluids. Mol Cell Proteomics. 2005;4:618–625
  193. Imanguli MM, Atkinson JC, Harvey KE, et al. Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation. Exp Hematol. 2007;35:184–192
  194. Colquhoun DR, Goldman LR, Cole RN, et al. Global screening of human cord blood proteomes for biomarkers of toxic exposure and effect. Environ Health Perspect. 2009;117(5):832–838
  195. Farrugia A, Robert P. Plasma protein therapies: current and future perspectives. Best Pract Res Clin Haematol. 2006;19(1):243–258
  196. Burnouf T. Plasma fractionation in the world: current status. Transfus Clin Biol. 2007;14(1):41–50
  197. Brigulla M, Thiele T, Scharf C, et al. Proteomics as a tool for assessment of therapeutics in transfusion medicine: evaluation of prothrombin complex concentrates. Transfusion. 2006;46:377–385
  198. Liumbruno G, Bennardello F, Lattanzio A, Piccoli P. Recommendations for the transfusion of plasma and platelets. Blood Transfus. 2009;7:132–150
  199. Köhler M, Hellstern P, Lechler E, Uberfuhr P, Müller-Berghaus G. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates. Thromb Haemost. 1998;80:399–402
  200. Demelbauer UM, Plematl A, Josic D, Allmaier G, Rizzi A. On the variation of glycosylation in human plasma derived antithrombin. J Chromatogr A. 2005;1080(1):15–21
  201. Plematl A, Demelbauer UM, Josic D, Rizzi A. Determination of the site-specific and isoform-specific glycosylation in human plasma-derived antithrombin by IEF and capillary HPLC–ESI-MS/MS. Proteomics. 2005;5(15):4025–4033
  202. Kovac S, Yang X, Huang F, Hixson D, Josic D. Proteomics as a tool for optimization of human plasma protein separation. J Chromatogr A. 2008;1194(1):38–47
  203. Yang X, Clifton J, Huang F, Kovac S, Hixson DC, Josic D. Proteomic analysis for process development and control of therapeutic protein separation from human plasma. Electrophoresis. 2009;30(7):1185–1193
  204. Eden E, Turino GM. Alpha 1-antitrypsin deficiency: lessons from longevity. Chest. 2009;135(3):591–592
  205. Kanazawa S, Kinoshita Y, Nakagawa Y, et al. Pneumothorax associated with alpha1-antitrypsin deficiency. Intern Med. 2009;48(5):387–388
  206. Campos MA, Alazemi S, Zhang G, Wanner A, Sandhaus RA. Effects of a disease management program in individuals with alpha-1 antitrypsin deficiency. COPD. 2009;6(1):31–40
  207. Yu M, Wang XX, Zhang FR, et al. Proteomic analysis of the serum in patients with idiopathic pulmonary arterial hypertension. J Zhejiang Univ Sci B. 2007;8(4):221–227
  208. Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia. 2007;13(5):65–68
  209. Righetti PG, Boschetti E. Sherlock Holmes and the proteome—a detective story. FEBS J. 2007;274(4):897–905
  210. Herosimczyk A, Dejeans N, Sayd T, Ozgo M, Skrzypczak WF, Mazur A. Plasma proteome analysis: 2D gels and chips. J Physiol Pharmacol. 2006;57(7):81–93
  211. Anstee DJ. Whatomics. Vox Sang. 2004;87(1):13–14
  212. Kitano H. Introductions to systems biology. Tanpakushitsu Kakusan Koso. 2003;48(7):789–793
  213. Friboulet A, Thomas D. Systems biology—an interdisciplinary approach. Biosens Bioelectron. 2005;20(12):2404–2407
  214. Liotta LA, Petricoin EF. Putting the “bio” back into biomarkers: orienting proteomic discovery toward biology and away from the measurement platform. Clin Chem. 2008;54(1):3–5
  215. Tissot JD, Schneider P. In:  Hondermarck H editors. Proteomics: biomedical and pharmaceutical applications. Amsterdam: Kluwer Academic Publishers; 2004;p. 57–99

PII: S1040-8428(10)00010-7

doi: 10.1016/j.critrevonc.2010.01.009

Critical Reviews in Oncology / Hematology
Volume 76, Issue 3 , Pages 153-172 , December 2010

Article Tools

* Image Usage & Resolution